Supernus Pharmaceuticals, Inc. (SUPN) Q4 2012 Earnings Results

Supernus Pharmaceuticals Misses on EPS, Stock Down 3.63%

Supernus Pharmaceuticals reported a wider-than-expected loss per share, which contributed to a negative stock reaction, with shares falling 3.63%. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. Management's defensive tone suggests they are navigating a challenging environment but are committed to long-term strategies.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.51	N/A	+30.52%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about current market conditions impacting performance. They remain focused on strategic initiatives to drive future growth.

Management highlighted ongoing challenges in the market.

They emphasized a focus on long-term strategies despite short-term setbacks.

Supernus Pharmaceuticals Misses on EPS, Stock Down 3.63%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Misses on EPS, Stock Down 3.63%

Key numbers

Management commentary